Status:
RECRUITING
Indocyanine Green (ICG) Guided Tumor Resection
Lead Sponsor:
St. Jude Children's Research Hospital
Conditions:
Neoplastic Disease
Solid Tumor
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is c...
Detailed Description
This trial is a single center open-label study. Patients with a solid tumor or lymphoma who require resection either for therapeutic or diagnostic intent will be included. Indocyanine Green (ICG) is ...
Eligibility Criteria
Inclusion
- Patients with a primary or relapsed solid tumor or lymphoma who require excision of the tumor or metastatic lesions.
Exclusion
- Subjects with a history of iodide allergies.
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
- Patients with benign pathology.
- Patients with brain tumors.
- Pregnant female.
- Patients with unilateral Wilms Tumor.
Key Trial Info
Start Date :
February 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT04084067
Start Date
February 7 2020
End Date
December 31 2027
Last Update
November 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105